Browse by Audience
Skip to content
Papers of the Week
[Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?]
Abstract
Migraine is a highly prevalent neurological disease and the search for an effective treatment to improve the patient's quality of life is essential. In 2018, anti-CGRP monoclonal antibodies were approved in Spain as a preventive treatment, and have proved to be effective in reducing the number of migraine crisis per month compared to placebo.